AC
TRVI icon

Armistice Capital’s Trevi Therapeutics TRVI Stock Holding History

Armistice Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,988,000
Closed -$18.8M – 272
2025
Q1 		$18.8M Buy
+2,988,000
New +$14.3M 0.5% 67
2022
Q4 		– Sell
-864,000
Closed -$1.33M – 237
2022
Q3 		$1.33M Buy
864,000
+448,000
+108% +$1.47M 0.03% 133
2022
Q2 		$1.17K Buy
+416,000
New +$1.02M 0.02% 123
2022
Q1 		– Sell
-1,512,344
Closed -$1.18M – 186
2021
Q4 		$1.18M Buy
+1,512,344
New +$1.59M 0.03% 127

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return